This new, expanded indication supplements the original 2008 FDA approval of FUSILEV. The drug is also indicated for rescue after high-dose methotrexate therapy in osteosarcoma and for diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.
Read the news release about the FDA approval of FUSILEV.
Related Articles on Colorectal Cancer:
Protein Biomarker Linked to Better Colorectal Cancer Survival for Obese
Study: Breast, Ovarian Cancer Drug May Have Utility in Treating Colorectal Cancer
Office Desk Jobs Double Colon Cancer Risk
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
